Updated 08:05 GMT, 20 Nov 2026 SPX 7,175.83 -2.02% NDX 26,517.05 -2.21% VIX 28.44 +15.80% GOLD 3,574.90 -3.00% CL 82.63 -0.70% BTC 61,735.58 -0.27%
NAS100 26,517 −2.21% S&P 7,176 −2.02% GOLD $3,575 −3.00% BTC $61,736 −0.27% VIX 28.44 +15.80% latest tape · as of 08:05 UTC
The Screen · Consumer Cyclical · Auto Parts

Gentex Corporation

GNTX · Nasdaq · USD · Market cap $3.9B · 6,398 employees

Gentex Corporation designs, develops, manufactures, markets, and supplies digital vision, connected car, dimmable glass, fire protection technologies, audio products, medical devices, and consumer electronics.

Not yet scored
19.17 USD

Price as of 19 Nov 2026Daily close, not a live quote

Screened 2026-11-19 · the tape above runs as of 08:05 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price19.17 USD at the 19 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 19 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenNot yet scored
  • OptionsOpen interest leans to puts (put/call 6.64)
  • Last reviewed19 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $28.73 to $38.66, base estimate $30.00 (screen dated 2026-11-19).

Current read
Distribution ?
Undervalued · screened 2026-11-19
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 6.64, read 2026-11-19
  • Ethical screen not yet scored
Price19.17 USD
Fair value30.00
Ethical score70.0/100
Value readUndervaluedas of 19 Nov 2026
Our investment reviews on this name
2026-10-30Read Distribution20.66-7.2% to today ✓Markdown gives way to Distribution after a 13% slide in 9 weeks
2026-08-31Read Markdown23.65-18.9% to today ✓Distribution gives way to Markdown with volume flow in agreement
2026-07-31Read Distribution24.35-21.3% to today ✓Markup gives way to Distribution after a 6% slide in 4 weeks
2026-07-02Read Markup25.86-25.9% to today First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Gentex Corporation holds its Distribution at $19.17. Elevated stress, defensive posture warranted, held for 7 days.

As held on the ledger · 2026-11-19
PhaseDistribution · caution
Quantitative stateElevated stress, defensive posture warranted, held for 7 days
Price at the screen$19.17
Valuation10.14 trailing · 8.88 forward price to earnings
Values screenNot scored · score 70.0
Beta0.85
The Workings

Five Screens: GNTX's Results

This security has not been fully scored against the values screen yet.

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 0.13% Below 33% Pass
Interest-bearing cash 0.18% Below 33% Pass
Receivables 17.56% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

The Read, in Plain English

Gentex clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.

2026-10-25

Gentex clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

2026-09-24 Clears

Gentex clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 19 Nov 2026: it trades at roughly a 36% discount to our $30.00 fair value.

Model construction and limits: fair-value methodology.

28.73Conservative30.00Base case38.66Growth case 19.17Price

Fair value range in USD, drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. A 36.1% discount to the base estimate.

The Street's Range
20.00Street low 24.00Street average 42.00Street high 19.17Price

Third-party analyst targets: 9 covering, consensus Hold. The average target sits +25% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $30.00, with a range of $28.73 to $38.66, dated to the 2026-11-19 screen.

How our estimate and third-party targets differ.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E8.9xvery cheap relative to earnings
Trailing P/E10.1xreasonably valued
EPS, trailing1.87
EPS, forward2.14
Revenue growth-1.1%revenue is shrinking
Profit margin15.1%healthy profit margins
Return on equity15.9%a solid return on shareholder capital
FCF yield8.47%
Dividend yield1.99%
Debt to equity0.30minimal debt: a conservative balance sheet
Current ratio2.92comfortably covers its short-term bills
Beta0.85steadier than the market
Short interest, float0.09%
52-week range18.89 - 26.48
Market cap$3.9B
Employees6,398

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-13 Distribution $19.37 -4.2% Entry 18

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29.

2026-11-06 Distribution $20.21 -2.2% Entry 17

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. Since the last review it its composite score eased.

2026-10-30 Distribution · changed $20.66 -2.8% Entry 16

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29.

2026-10-23 Markdown $21.26 +0.0% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-22 Markdown $21.26 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-21 Markdown $21.26 +0.7% Entry 13

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-20 Markdown $21.11 +0.0% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-19 Markdown $21.11 +0.0% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-18 Markdown $21.11 +0.0% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-17 Markdown $21.11 +0.0% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (9 analysts) rates it buy, with a mean price target of $29. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on GNTX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in GNTX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $23.20 +7.1% · $1,071 +7.1%
2 months $21.99 +13.0% · $1,130 +13.0%
3 months $21.19 +17.3% $0.12 $1,178 +17.8%
6 months $23.47 +5.9% $0.24 $1,069 +6.9%
1 year $21.81 +13.9% $0.48 $1,161 +16.1%
2 years $32.81 -24.3% $0.96 $786 -21.4%
3 years $26.18 -5.1% $1.44 $1,004 +0.4%
5 years $31.41 -20.9% $2.40 $867 -13.3%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever GNTX does next, these words stay.

Gentex Corporation · GNTX · Distribution · $19.17
Recorded 2026-11-19 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.